Pasithea Therapeutics (KTTA) Competitors $0.79 -0.03 (-3.71%) Closing price 10/9/2025 03:50 PM EasternExtended Trading$0.82 +0.02 (+3.16%) As of 10/9/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. RVPH, CING, ABP, APLM, CTXR, SYBX, FNCH, LEXX, PRPH, and NAIIShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Reviva Pharmaceuticals (RVPH), Cingulate (CING), Abpro (ABP), Apollomics (APLM), Citius Pharmaceuticals (CTXR), Synlogic (SYBX), Finch Therapeutics Group (FNCH), Lexaria Bioscience (LEXX), ProPhase Labs (PRPH), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors Reviva Pharmaceuticals Cingulate Abpro Apollomics Citius Pharmaceuticals Synlogic Finch Therapeutics Group Lexaria Bioscience ProPhase Labs Natural Alternatives International Reviva Pharmaceuticals (NASDAQ:RVPH) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Does the media refer more to RVPH or KTTA? In the previous week, Reviva Pharmaceuticals had 6 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.28 beat Reviva Pharmaceuticals' score of 0.72 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Positive Pasithea Therapeutics Positive Do institutionals and insiders hold more shares of RVPH or KTTA? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer RVPH or KTTA? Reviva Pharmaceuticals presently has a consensus price target of $4.86, suggesting a potential upside of 518.74%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility and risk, RVPH or KTTA? Reviva Pharmaceuticals has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Is RVPH or KTTA more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Pasithea Therapeutics N/A -88.60%-81.10% Which has better valuation & earnings, RVPH or KTTA? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-1.21Pasithea TherapeuticsN/AN/A-$13.90M-$7.55-0.10 SummaryReviva Pharmaceuticals beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.11M$3.36B$6.13B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-0.1021.3485.8327.64Price / SalesN/A474.18624.67141.10Price / CashN/A47.1938.3262.20Price / Book0.0710.4313.066.79Net Income-$13.90M-$52.40M$3.30B$275.88M7 Day Performance-0.63%4.97%3.71%1.90%1 Month Performance0.98%17.02%10.70%8.90%1 Year Performance-83.64%34.38%84.93%36.28% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.1983 of 5 stars$0.79-3.7%N/A-83.8%$6.11MN/A-0.103Positive NewsRVPHReviva Pharmaceuticals3.6909 of 5 stars$0.37+19.6%$4.86+1,217.7%-28.6%$21.38MN/A-0.575Analyst ForecastGap UpHigh Trading VolumeCINGCingulate2.5314 of 5 stars$3.92+0.8%$26.25+569.6%+0.2%$21.06MN/A-0.9620Analyst ForecastABPAbpro3.3033 of 5 stars$0.22-12.7%$4.00+1,684.1%N/A$20.59M$180K0.0015Analyst ForecastGap UpAPLMApollomics0.7594 of 5 stars$18.43+51.3%N/A+36.4%$20.34M$1.49M0.0045Analyst ForecastGap UpHigh Trading VolumeCTXRCitius Pharmaceuticals2.7112 of 5 stars$1.24+5.1%$53.00+4,174.2%-86.9%$20.07MN/A0.0020Analyst ForecastGap UpSYBXSynlogic0.7143 of 5 stars$1.68-1.2%N/A+17.1%$19.89MN/A-21.0080News CoveragePositive NewsAnalyst ForecastFNCHFinch Therapeutics Group0.7071 of 5 stars$12.28+0.2%N/A+5.7%$19.72MN/A-1.39190LEXXLexaria Bioscience2.8568 of 5 stars$0.95-3.1%$4.00+319.9%-70.0%$19.22M$460K-1.427News CoverageAnalyst ForecastPRPHProPhase Labs0.3595 of 5 stars$0.46+4.6%N/A-77.7%$18.19M$6.77M-0.36130Analyst ForecastGap UpNAIINatural Alternatives International1.2652 of 5 stars$2.84-2.6%N/A-40.8%$17.97M$129.86M-1.25290Analyst ForecastGap Down Related Companies and Tools Related Companies Reviva Pharmaceuticals Alternatives Cingulate Alternatives Abpro Alternatives Apollomics Alternatives Citius Pharmaceuticals Alternatives Synlogic Alternatives Finch Therapeutics Group Alternatives Lexaria Bioscience Alternatives ProPhase Labs Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia and AMD just surged. But this setup was already winning.Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredHave you heard of the Texas Royalty Plan?There is a backdoor way you could collect a check, four times a year, thanks to the exploding oil industry in ...Brownstone Research | SponsoredHow to Cash In on Trump’s Digital Current - Move By This ThursdayBitcoin Breakout: What Most Investors Are Missing Washington just approved more crypto legislation in 90 da...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
